Prostate cancer patients prefer mpMRI over biopsy

Low-risk prostate cancer patients who underwent multiparametric MRI (mpMRI)...Read more on AuntMinnie.comRelated Reading: Ga-68 PSMA PET/MRI, mpMRI work for prostate cancer analysis mpMRI reduces unnecessary prostate biopsies Choline-PET with mpMRI is cost-effective for prostate cancer Prostate imaging director can improve MRI efficiency mpMRI falls short for prostate cancer in African Americans
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

ADT is standard therapy for advanced and metastatic PC with negative metabolic consequences. We determined the metabolomic effects of ADT during the PC treatments. Such analysis identify the unexpected reduced ketogenesis and microbiome ‐associated metabolites during ADT AbstractAndrogen deprivation therapy (ADT) is the main treatment strategy for men with metastatic prostate cancer (PC). However, ADT is associated with various metabolic disturbances, including impaired glucose tolerance, insulin resistance and weight gain, increasing risk of diabetes and cardiovascular death. Much remains unknown about the metabolic pat...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
ConclusionThe results of this study showed that there are some differences in term of protein content between the normal and cancerous lung tissues. Further studies are needed to evaluate these proteins that investigate whether these proteins can candidate as biomarkers to use in the early diagnosis of patients with NSCLC.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Purpose: The availability of novel imaging modalities (NIM) in prostate cancer (PCa) has overtaken the evidence informing their use. The recent EORTC consensus statement on modern imaging recognises the need for large-scale clinical trials of novel imaging [1]. The UK environment is well placed to conduct such trials; the NCRI prostate cancer CSG wished to benchmark current UK imaging availability and practice to inform future national trials.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The role of pelvic nodal irradiation in prostate cancer remains controversial. Nevertheless, many high-risk patients are treated with prostate and pelvis radiotherapy in addition to androgen deprivation therapy (ADT) [1]. A recent retrospective study [2] and data from the UK Stampede control arm [3] suggest that radiotherapy may be of benefit to node positive patients. The aim of our study was to document outcomes in patients with node positive prostate cancer treated with pelvic nodal radiotherapy in a UK cancer centre.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Relapsed or progressive prostate cancer frequently manifests as consecutive PSA rises long before disease is clinically detectable. Imaging with novel radiotracers targeting prostate-specific membrane antigen (PSMA) has been shown to be more sensitive in identifying the site of disease at lower PSA levels compared with conventional imaging, which may provide increased opportunity for salvage therapy, more aggressive local management of oligometastatic disease or increased confidence in proceeding with systemic therapy [1].
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: To assess the benefits and risks of co-administering maintenance prednisolone with docetaxel and androgen-deprivation therapy (ADT) in hormone sensitive metastatic prostate cancer (HSMPC).
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: As doctors we are required to take consent for radiotherapy; we typically take written consent [1]. We must tell a patient if a treatment might result in a serious adverse outcome, even if the likelihood is very small [2]. As many cancer centres move towards tumour site-specific consent forms for prostate radiotherapy we wanted to ascertain if there was consensus.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
In this study, we describe our experience with both drugs at the Diana Princess of Wales Hospital (DPoW), Grimsby.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The STAMPEDE trial has recently shown a benefit in overall survival by irradiating the prostate of patients with newly diagnosed metastatic prostate cancer [1]. This benefit was only shown in patients with low burden of metastatic disease, as per the CHAARTED criteria [2]. The current standard of care for these patients is androgen deprivation therapy ± docetaxel chemotherapy and radiotherapy to symptomatic areas of disease if required. The aim of this audit is to determine the potential number of men with low burden of metastatic disease who may require additional radiotherapy.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Radiotherapy to the prostate in mHSPC improves overall survival and progression-free survival (PFS) for patients with low-volume disease [1]. Radium-223 in metastatic castration resistant prostate cancer improves overall survival [2]. We conducted a prospective phase I/II clinical trial in mHSPC, testing the combination of LHRHa with concurrent pelvic radiotherapy and radium-223.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
More News: African Health | Cancer | Cancer & Oncology | Prostate Cancer | Radiology